CL2021001248A1 - Métodos de tratamiento para la fibrosis quística - Google Patents
Métodos de tratamiento para la fibrosis quísticaInfo
- Publication number
- CL2021001248A1 CL2021001248A1 CL2021001248A CL2021001248A CL2021001248A1 CL 2021001248 A1 CL2021001248 A1 CL 2021001248A1 CL 2021001248 A CL2021001248 A CL 2021001248A CL 2021001248 A CL2021001248 A CL 2021001248A CL 2021001248 A1 CL2021001248 A1 CL 2021001248A1
- Authority
- CL
- Chile
- Prior art keywords
- cystic fibrosis
- treatment methods
- pharmaceutically acceptable
- acceptable salt
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Esta solicitud describe métodos para tratar la fibrosis quística o una enfermedad mediada por CFTR que comprende administrar el Compuesto I o una sal farmacéuticamente aceptable de este. La solicitud describe además composiciones farmacéuticas que comprenden el Compuesto I o una sal farmacéuticamente aceptable de este y que comprende opcionalmente uno o más agentes moduladores de CFTR adicionales.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862767202P | 2018-11-14 | 2018-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021001248A1 true CL2021001248A1 (es) | 2021-11-26 |
Family
ID=68808572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021001248A CL2021001248A1 (es) | 2018-11-14 | 2021-05-12 | Métodos de tratamiento para la fibrosis quística |
Country Status (22)
Country | Link |
---|---|
US (1) | US20220047564A1 (es) |
EP (2) | EP4218754A3 (es) |
AU (1) | AU2019381750A1 (es) |
BR (1) | BR112021009145A2 (es) |
CA (1) | CA3123578A1 (es) |
CL (1) | CL2021001248A1 (es) |
CO (1) | CO2021007447A2 (es) |
DK (1) | DK3880197T3 (es) |
EA (1) | EA202191361A1 (es) |
ES (1) | ES2943126T3 (es) |
FI (1) | FI3880197T3 (es) |
HR (1) | HRP20230272T1 (es) |
HU (1) | HUE061686T2 (es) |
IL (1) | IL282988A (es) |
LT (1) | LT3880197T (es) |
MA (1) | MA54227B1 (es) |
MD (1) | MD3880197T2 (es) |
PL (1) | PL3880197T3 (es) |
PT (1) | PT3880197T (es) |
RS (1) | RS64192B1 (es) |
SI (1) | SI3880197T1 (es) |
WO (1) | WO2020102346A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112020010335A2 (pt) * | 2017-12-01 | 2020-11-10 | Vertex Pharmaceuticals Incorporated | processos para produzir moduladores de regulador de condutância de transmembrana de fibrose cística |
SG11202006614VA (en) | 2018-02-15 | 2020-08-28 | Vertex Pharma | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
JP2022544383A (ja) * | 2019-08-14 | 2022-10-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Cftrモジュレータの結晶形態 |
IL303519A (en) | 2020-12-10 | 2023-08-01 | Vertex Pharma | Cystic fibrosis treatment methods |
WO2023150237A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2023150236A1 (en) | 2022-02-03 | 2023-08-10 | Vertex Pharmaceuticals Incorporated | Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol |
WO2023154291A1 (en) | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
WO2023224931A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2023224924A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a macrocyclic compounds as cftr modulators and their preparation |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
HUP0501067A2 (en) | 2001-11-14 | 2006-02-28 | Teva Pharma | Amorphous and crystalline forms of losartan potassium and process for their preparation |
ATE534383T1 (de) | 2006-05-12 | 2011-12-15 | Vertex Pharma | Zusammensetzungen aus n-ä2,4-bis(1,1- dimethylethyl)-5-hydroxyphenylü-1,4-dihydro-4- oxochinolin-3-carboxamid |
EP3842037A1 (en) | 2008-08-13 | 2021-06-30 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
AR073709A1 (es) | 2008-09-29 | 2010-11-24 | Vertex Pharma | Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico |
AU2011230508B2 (en) | 2010-03-25 | 2016-04-28 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihyderoxypropyl)-6-fluoro-2- (1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide |
HUE056525T2 (hu) | 2010-04-07 | 2022-02-28 | Vertex Pharma | 3-(6-(1-(2,2-Difluorbenzo[d][1,3]dioxol-5-il)ciklopropánkarboxamido)-3-metilpiridin-2-il)benzoesav gyógyszerészeti készítményei és azok adagolása |
NZ603042A (en) | 2010-04-22 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
MX353408B (es) | 2010-04-22 | 2018-01-11 | Vertex Pharma | Proceso para producir compuestos de cicloalquilcarboxamido-indol. |
EP2608775A2 (en) | 2010-08-27 | 2013-07-03 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
HUE047354T2 (hu) | 2011-05-18 | 2020-04-28 | Vertex Pharmaceuticals Europe Ltd | Ivacaftor deuterizált származékai |
IL265430B1 (en) | 2012-02-27 | 2024-04-01 | Vertex Pharma | Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof |
AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
EP2914248B2 (en) | 2012-11-02 | 2023-10-18 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cftr mediated diseases |
WO2015160787A1 (en) | 2014-04-15 | 2015-10-22 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
CN112279808B (zh) | 2014-10-06 | 2024-03-08 | 弗特克斯药品有限公司 | 囊性纤维化跨膜转导调节因子调节剂 |
US20180353500A1 (en) | 2015-09-21 | 2018-12-13 | Vertex Pharmaceuticals (Europe) Limited | Administration of deuterated cftr potentiators |
PE20191147A1 (es) | 2016-09-30 | 2019-09-02 | Vertex Pharma | Modulador de regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador |
AU2017352206B2 (en) | 2016-10-27 | 2022-03-03 | Vertex Pharmaceuticals (Europe) Limited | Methods of treatment with deuterated CFTR potentiators |
EP3654969A1 (en) * | 2017-07-17 | 2020-05-27 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
WO2019018353A1 (en) * | 2017-07-17 | 2019-01-24 | Vertex Pharmaceuticals Incorporated | METHODS OF TREATING CYSTIC FIBROSIS |
TWI810243B (zh) * | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
SG11202006614VA (en) | 2018-02-15 | 2020-08-28 | Vertex Pharma | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them |
-
2019
- 2019-11-13 AU AU2019381750A patent/AU2019381750A1/en active Pending
- 2019-11-13 ES ES19817037T patent/ES2943126T3/es active Active
- 2019-11-13 HU HUE19817037A patent/HUE061686T2/hu unknown
- 2019-11-13 EP EP23154663.1A patent/EP4218754A3/en active Pending
- 2019-11-13 MA MA54227A patent/MA54227B1/fr unknown
- 2019-11-13 SI SI201930490T patent/SI3880197T1/sl unknown
- 2019-11-13 LT LTEPPCT/US2019/061171T patent/LT3880197T/lt unknown
- 2019-11-13 US US17/293,632 patent/US20220047564A1/en active Pending
- 2019-11-13 FI FIEP19817037.5T patent/FI3880197T3/fi active
- 2019-11-13 EA EA202191361A patent/EA202191361A1/ru unknown
- 2019-11-13 BR BR112021009145-9A patent/BR112021009145A2/pt unknown
- 2019-11-13 CA CA3123578A patent/CA3123578A1/en active Pending
- 2019-11-13 EP EP19817037.5A patent/EP3880197B1/en active Active
- 2019-11-13 PT PT198170375T patent/PT3880197T/pt unknown
- 2019-11-13 WO PCT/US2019/061171 patent/WO2020102346A1/en unknown
- 2019-11-13 HR HRP20230272TT patent/HRP20230272T1/hr unknown
- 2019-11-13 PL PL19817037.5T patent/PL3880197T3/pl unknown
- 2019-11-13 MD MDE20210905T patent/MD3880197T2/ro unknown
- 2019-11-13 DK DK19817037.5T patent/DK3880197T3/da active
- 2019-11-13 RS RS20230317A patent/RS64192B1/sr unknown
-
2021
- 2021-05-06 IL IL282988A patent/IL282988A/en unknown
- 2021-05-12 CL CL2021001248A patent/CL2021001248A1/es unknown
- 2021-06-08 CO CONC2021/0007447A patent/CO2021007447A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2021007447A2 (es) | 2021-12-10 |
HRP20230272T1 (hr) | 2023-04-28 |
US20220047564A1 (en) | 2022-02-17 |
MA54227B1 (fr) | 2023-03-31 |
DK3880197T3 (da) | 2023-03-27 |
MA54227A (fr) | 2021-09-22 |
BR112021009145A2 (pt) | 2021-08-10 |
WO2020102346A1 (en) | 2020-05-22 |
SI3880197T1 (sl) | 2023-04-28 |
MD3880197T2 (ro) | 2023-08-31 |
LT3880197T (lt) | 2023-05-10 |
AU2019381750A1 (en) | 2021-06-24 |
PT3880197T (pt) | 2023-05-09 |
EP3880197B1 (en) | 2023-02-22 |
EP3880197A1 (en) | 2021-09-22 |
CA3123578A1 (en) | 2020-05-20 |
PL3880197T3 (pl) | 2023-07-31 |
HUE061686T2 (hu) | 2023-08-28 |
IL282988A (en) | 2021-06-30 |
EP4218754A2 (en) | 2023-08-02 |
RS64192B1 (sr) | 2023-06-30 |
EP4218754A3 (en) | 2023-08-16 |
ES2943126T3 (es) | 2023-06-09 |
FI3880197T3 (fi) | 2023-05-04 |
EA202191361A1 (ru) | 2021-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021007447A2 (es) | Métodos de tratamiento para la fibrosis quística | |
CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
CL2020000122A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
PE20220170A1 (es) | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quistica | |
CL2019001842A1 (es) | Nuevos derivados de fenilo. | |
CO6361942A2 (es) | Terapia de combinacion con epoxicetonas peptidicas | |
BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
CL2023002383A1 (es) | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d | |
MX2020004187A (es) | Composicion farmaceutica topica de adapaleno y minociclina. | |
CL2020002512A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak. | |
AR102973A1 (es) | Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende | |
AR058194A1 (es) | Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide | |
AR101740A1 (es) | Terapia de combinación y composiciones | |
BR112022003434A2 (pt) | Composição de liberação retardada de niclosamida e uso antiviral da mesma | |
CY1121345T1 (el) | Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης | |
BR112022014861A2 (pt) | Métodos de tratamento para deficiência de alfa-1 antittripsina | |
AR119159A1 (es) | Tratamientos de angioedema | |
BR112020021631A8 (pt) | Composto oxo-substituído | |
CL2022001314A1 (es) | Fármaco para el tratamiento o la prevención de la hemorragia cerebral, y método para el tratamiento o la prevención de la hemorragia cerebral con dicho fármaco | |
AR110913A1 (es) | Compuesto aminoglucósido y su uso para prevenir o tratar enfermedades infecciosas | |
BR112022001514A2 (pt) | Composição farmacêutica multicamada e processo para a preparação de uma composição farmacêutica | |
AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol | |
AR109209A1 (es) | Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas | |
AR108792A1 (es) | Composiciones que comprenden timolol |